AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

1CellBio Announces Custom Targeted Bead Program to Accelerate Next Phase in Single-Cell Analysis

April 17, 2019 GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr 17, 2019--1CellBio, Inc., today announced a new program to supply select customers with its proprietary inDrop™ hydrogel beads synthesized with custom primers that target user-specified transcripts.

“This new program enables researchers to focus their sequencing depth on their genes of interest rather than the full transcriptome,” said Colin J.H. Brenan, PhD, Chief Executive Officer at 1CellBio. “We believe the ability to customize and target transcriptional regions of interest will accelerate clinical and pharmaceutical research applications of single-cell RNA-seq.”

The inDrop technology enables researchers to run full transcriptomic analysis with single cells. Rather than binding the full spectrum of mRNAs, this new program provides custom targeted beads to capture transcripts of a very specific set of user-selected genes within single cells. Some of the potential applications for the targeted beads might be custom oncogene panels, immunoprofiling for antibodies and T-cell receptors, or mRNA isoform detection.

“Using the inDrop whole-transcriptome approach, our customers are discovering key genes that are differentially expressed between cell types. This program will broaden the technology to develop new applications by providing specific DNA oligonucleotides on inDrop hydrogel beads,” said Mike Kopczynski, Chief Operating Officer at 1CellBio. “Custom panels for targeted transcript capture are the natural next phase in single-cell analysis.”

About 1CellBio
1CellBio Inc. is a leading single-cell analysis company serving the biomedical research community. The company’s flagship inDrop™ System, a high-resolution, single-cell transcriptomics platform, delivers greater experimental control, rare actionable information and lower overall cost per result compared to all other existing platforms. Research laboratories around the world are now adopting the platform for a wide range of single-cell applications from tumor profiling to stem cells to embryo development to the identification and validation of new drug targets. Founded by a group of prominent scientists at Harvard University, 1CellBio is based in Watertown, Mass., and the company supports its growing number of customers through a team of international sales and field application scientists. For more information, please visit  www.1cell-bio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190417005167/en/

CONTACT: Andrew Noble

(415) 722-2129

andrew_noble@noblecomms.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: 1CellBio, Inc.

Copyright Business Wire 2019.

PUB: 04/17/2019 08:00 AM/DISC: 04/17/2019 08:00 AM

http://www.businesswire.com/news/home/20190417005167/en